Velafaks - instruction , application reviews


1. active substance

2. Product form

3. Composition

4. Indications

5. Contraindications

6. dosage and Administration

7. Side effects

8. Cautions

9. Conditions and terms

Velafaks - antidepressant drug.

active substance

Venlafaxine (Venlafaxine).

Product form

Velafaks is available in tablet form for oral administration.The preparation is realized in blisters (Table 14. Each), placed in cardboard boxes 2 and 4 pcs.



Table 1.

Venlafaxine hydrochloride

(which is equivalent to the contents of venlafaxine)

42.43 mg

84.86 mg

37.5 mg

75 mg

Excipients: sodium carboxymethyl starch, microcrystallinecellulose, corn starch, talc, iron oxide yellow dye (E172), magnesium stearate, colloidal silicon dioxide.

Indications Indications for Velafaksa is a depression therapy of various origins, including depression accompanied by symptoms of anxiety.

Contraindications Contraindications to receivin

g the drug are:

  • severe functional impairment of hepatic and / or renal impairment (Cl creatinine less than 10 mL / min).
  • Joint reception of MAO inhibitors.
  • Children and teens under 18 years of age.
  • Pregnancy and breast-feeding (lactation).
  • Individual hypersensitivity to venlafaxine and other ingredients of the drug.

Velafaks appointed with extreme caution when: unstable angina, myocardial infarction (recently adjourned), tachycardia, seizures in the patient's history, angle-closure glaucoma, increased intraocular pressure, hyponatremia, manic states in history, hypovolemia, coadministration of diuretics, dehydration,initial weight loss, suicidal tendencies, predisposition to bleeding from the mucous membranes and skin.

Method of use and dosage

drug is intended for oral use.Tablets should be taken with liquid, during a meal, preferably at the same time, drinking plenty of water.

For the treatment of depressive state the recommended initial dose is Velafaksa - by 37.5 mg 2 times daily.In the event that after several weeks of treatment, a significant improvement is observed, the dose can be increased to 150 mg per day (divided into two doses of 75 mg).

If necessary, use of the drug at a higher dose in patients with severe depressive illness, or other conditions that require treatment in a hospital, you can immediately take 75 mg 2 times a day.Thereafter, the daily dose can be increased to 75 mg every 2-3 days until the desired therapeutic effect.The maximum permitted daily dose is 375 mg.Once the desired therapeutic effect is achieved daily dose can be gradually reduced to the minimum effective level.When

mild renal insufficiency (glomerular filtration rate of 30 ml / min) no dosing regime should be adjusted.

In-severe renal insufficiency (glomerular filtration rate less than 10 mL / min) using Velafaksa not recommended, as the experience of this treatment is limited.When

moderate renal insufficiency (glomerular filtration rate of 10-30 ml / min), the dose should be reduced by 25-50%.In connection with the elongation of T1 / 2 of venlafaxine such patients are required to take the entire dose one time per day.

Patients who are on hemodialysis may receive 50% of the usual daily dose of venlafaxine after hemodialysis.

correction mode is not necessary Mild hepatic insufficiency.In moderate hepatic insufficiency the dose should be reduced by 50%.Velafaksa use is not recommended in severe hepatic insufficiency, since the experience of this treatment is limited.

Older patients do not need a dose adjustment, however, during treatment should be careful, for example, due to the risk of functional disorders of the kidneys.In this regard, patients in this group must be assigned the lowest effective dose of the drug, and if necessary increase dose recommended careful medical supervision.

At the end of therapy the dose must be reduced gradually.When using the drug in doses greater than or equal to 75 mg, the course of 7 days or more, Velafaks cancel within a week (at least), gradually reducing the dose.When taken in high doses over the course of 6 weeks, the period required for stopping the drug is at least 2 weeks.The appearance of signs of relapse of the disease during the period of cancellation Velafaksa requires the appointment of the initial dose or a longer and gradually reduce it.

Side effects

use of the drug may cause the following side effects:

  • central and peripheral nervous system: often - fatigue, dizziness, nightmares, drowsiness, insomnia, fatigue, paresthesia, sedation, muscle hypertonicity, increased nervousexcitability, tremors, stupor, yawning;rarely - hallucinations, syncope, myoclonus, apathy;rarely - ataxia with impaired movement coordination and balance, convulsions, hypomania or mania, speech disorder, serotonin syndrome, seizures, symptoms resembling neuroleptic malignant syndrome;in some cases - extrapyramidal disorders (including dystonia and dyskinesia), nonsense, akathisia / psychomotor restlessness, tardive dyskinesia.
  • Cardiovascular System: Frequent - flushing of the skin, increased blood pressure;infrequently - postural hypotension, arrhythmia, syncope, tachycardia, decreased blood pressure;very rarely - lengthening the interval QT, arrhythmia of the type "pirouette", ventricular fibrillation, ventricular tachycardia.
  • digestive system: often - constipation, nausea, vomiting, loss of appetite, dry mouth, abdominal pain, dyspepsia;rare - increase in liver enzymes, bruxism;rarely - hepatitis;in some cases - pancreatitis.
  • urinary system: often - a violation of urination;Infrequent - urinary retention.
  • Sexual system: often - erectile dysfunction and / or ejaculation, decreased libido, menorrhagia, anorgasmia in men;infrequently - anorgasmia in women, menstrual disorders.
  • Respiratory system: in some cases - pulmonary eosinophilia;rarely - shortness of breath.
  • endocrine system: in some cases - increased concentration of prolactin;rarely - galactorrhea.
  • Musculoskeletal System: often - myalgia, arthralgia;rarely - muscle spasms;in some cases - rhabdomyolysis.
  • lymphatic system and blood formation system : rarely - hemorrhagic syndrome, bleeding in the mucous membranes and skin (ecchymosis), prolonged bleeding time, thrombocytopenia;in some cases - aplastic anemia, agranulocytosis, pancytopenia and neutropenia.
  • Metabolism : often - increase or decrease in body weight, elevated levels of serum cholesterol (especially after taking Velafaksa in high doses or long-term drug treatment);infrequently - inadequate secretion syndrome of antidiuretic hormone (ADH), hyponatremia;in some cases - increase in the concentration of plasma prolactin.
  • Senses : often - mydriasis, accommodation disturbances, ringing or noise in the ears, blurred vision;sometimes - a violation of taste sensations.
  • Skin and appendages : often - excessive sweating (including night);sometimes - alopecia.
  • Mental status : depression, suicidal thoughts and behavior during treatment and after drug withdrawal (frequency unknown).
  • Allergic manifestations : rarely - itching, hives, skin rash (including maculopapular), photosensitivity, angioedema;rarely - Stevens-Johnson syndrome, erythema multiforme exudative;in some cases - anaphylactic reaction.

Overdose symptoms: dizziness, ventricular and sinus bradycardia or tachycardia, convulsions, decreased blood pressure, impaired consciousness (from somnolence to coma), ECG changes (bundle branch block, prolongation of the interval QT, an extension of the QRS complex), the lethalExodus.These symptoms occur mainly while taking ethanol.


Patients and people engaged in caring for the sick, it is necessary to warn of the need to monitor for the emergence of suicidal ideation and immediately seek medical care when a corresponding indication.

Like other antidepressants, Velafaks should be administered with extreme caution to persons with a history of seizures.Treatment with venlafaxine should be discontinued in the development of epileptic seizures.The drug is not recommended in patients with uncontrolled epilepsy and patients with controlled epilepsy need medical observation.

use of the drug may be associated with the emergence of psychomotor restlessness, which resemble clinical features akathisia.Thus patients experience need not move and can stand or sit in one place.This state often lasts for the first few weeks of therapy.When these symptoms increase in dose may be adversely affected, so it is advisable to consider continuing the reception Velafaksa.

Patients should be warned about the need for immediate treatment to the doctor with the appearance of hives, rashes or other allergic reactions.

Patients taking the drug, rarely noted changes in ECG parameters (extension of the QRS complex, prolongation of the interval PR and QT).

Patients, especially the elderly, need to warn about the possibility of imbalance and feelings of dizziness (orthostatic hypotension).Venlafaxine

as other serotonin reuptake inhibitors, may increase the risk of hemorrhages in the skin and mucous membranes.When treating patients predisposed to these conditions, you need to exercise caution.

Velafaksa During the reception, especially in reducing the volume of circulating blood or dehydration (including patients receiving diuretics and elderly patients), there may be inadequate secretion of antidiuretic hormone syndrome and / or hyponatremia.

When using venlafaxine over a long period of time necessary to monitor the concentration of serum cholesterol.

While receiving Velafaksa mydriasis can be observed, it is recommended to control intraocular pressure in patients with angle-closure glaucoma.

During therapy prohibits the use of alcoholic beverages.

venlafaxine is not desirable to combine with the drugs that reduce the body weight (including phentermine), due to lack of information on the safety and efficacy.

While taking Velafaksa, be careful during the execution of electroconvulsive therapy (as the experience in the use of venlafaxine in these conditions is absent).

Venlafaxine has virtually no effect on cognitive and psychomotor functions.However, given the existing risk of significant side effects from the CNS during venlafaxine therapy requires careful when driving and occupation of potentially hazardous activities requiring psychomotor speed of reaction and high concentration.

Conditions and terms

Store in a cool, dry place, out of direct sunlight at a temperature not exceeding 25 ° C.Keep away from children.Shelf life - 3 years.


Product description posted on this page is a supplement and a simplified version of the official version of the annotations to the drug.The information is provided for informational purposes only and is not a guide to self-medication.Before using the product you should consult with a specialist and to get acquainted with the instructions approved by the manufacturer.

Latest Blog Post

Miakaltsik - instruction , application reviews
December 12, 2017

Miacalcic is a medicament that affects the phosphorus-calcium metabolism used to treat osteoporosis. Active ingredient Calcitonin( Calcitoni...

Metacin - instruction , application reviews
December 12, 2017

Metacin is a drug used to treat spasms. Metacin is a drug that helps to reduce the tone of internal organs, as well as to reduce the secretion of ...

Metamizole - instruction , application reviews
December 12, 2017

Metamizole sodium( Metamizole sodium) belongs to the group of analgesic narcotics that nonselectively block COX and reduce the formation of Pg fro...